middle.news
Argenica Completes Phase 2 Stroke Trial Dosing Amid FDA Clinical Hold
8:52am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
Argenica Completes Phase 2 Stroke Trial Dosing Amid FDA Clinical Hold
8:52am on Wednesday 23rd of July, 2025 AEST
Key Points
Final patient dosed in Phase 2 acute ischaemic stroke trial
Topline Phase 2 data expected in Q3 2025
FDA places clinical hold on US IND application for ARG-007
Positive preclinical data supports ARG-007 development in traumatic brain injury
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE